We are actively seeking investors to complete our regulatory and clinical development plan.
Our lead product candidate HIV vaccine has completed three clinical trials, demonstrating safety and efficacy. We have submitted a request for Breakthrough Therapy Designation but in order for the FDA to make a determination on our request we must submit additional information from our clinical trials. Unfortunately we have run out of funds at the final step. We believe DermaVir represents a paradigm shift in HIV treatment, and are committed to submitting to the agency all requested documents. If approved the global impact would benefit 30+ million HIV infected people. We believe it is imperative to finish this process.
Please contacts us to discuss our funding needs in order to achieve FDA guidance on requirements for approval.
Please e-mail us to discuss: